134 related articles for article (PubMed ID: 36937430)
1. Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer.
Chen L; Jiang H; Rao JJ; Wang LS; Yan W; Ye J; Lou J
Front Oncol; 2023; 13():1146362. PubMed ID: 36937430
[TBL] [Abstract][Full Text] [Related]
2. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I
Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study.
Kang M; Xue F; Xu S; Shi J; Mo Y
Radiol Oncol; 2023 Sep; 57(3):405-410. PubMed ID: 37494583
[TBL] [Abstract][Full Text] [Related]
4. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.
Wang HY; Chu JF; Zhao Y; Tang H; Wang LL; Zhou MQ; Yan Z; Liu YY; Yao ZH
Cancer Manag Res; 2020; 12():3827-3834. PubMed ID: 32547218
[TBL] [Abstract][Full Text] [Related]
5. A Receiver Operating Characteristic Framework for Non-adherence Detection Using Drug Concentration Thresholds-Application to Simulated Risperidone Data in Schizophrenic Patients.
Pérez-Ruixo C; Remmerie B; Peréz-Ruixo JJ; Vermeulen A
AAPS J; 2019 Mar; 21(3):40. PubMed ID: 30874997
[TBL] [Abstract][Full Text] [Related]
6. Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy.
Fukuda N; Akamine Y; Abumiya M; Takahashi S; Yoshioka T; Kameoka Y; Takahashi N; Miura M
Cancer Chemother Pharmacol; 2022 May; 89(5):609-616. PubMed ID: 35316401
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab.
Jiang F; Li J; Kong X; Sun P; Qu H
Front Pharmacol; 2022; 13():973448. PubMed ID: 36238567
[No Abstract] [Full Text] [Related]
8. Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma.
Noda S; Iida H; Fujimoto T; Wakasugi Y; Yabuta N; Sudou M; Hira D; Tani M; Andoh A; Morita SY; Terada T
Cancer Chemother Pharmacol; 2021 Aug; 88(2):281-288. PubMed ID: 33928425
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.
Kenmotsu H; Imamura CK; Kawamura T; Oyakawa T; Omori S; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Yamamoto N; Takahashi T; Tanigawara Y
Cancer Chemother Pharmacol; 2022 Aug; 90(2):115-123. PubMed ID: 35821437
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
Jiang HT; Li W; Zhang B; Gong Q; Qie HL
Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
Xiang M; Yang X; Ren S; Du H; Geng L; Yuan L; Wen Y; Lin B; Li J; Zhang Y; Feng G; Du X
Oncologist; 2021 Dec; 26(12):e2130-e2135. PubMed ID: 34423518
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer.
Zhai C; Zhang X; Ren L; You L; Pan Q; Pan H; Han W
Front Oncol; 2020; 10():619010. PubMed ID: 33680942
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer.
Huang M; Liu Y; Yu M; Li Y; Zhang Y; Zhu J; Li L; Lu Y
Invest New Drugs; 2022 Apr; 40(2):308-313. PubMed ID: 34724131
[TBL] [Abstract][Full Text] [Related]
15. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study.
Cerbone L; Combarel D; Geraud A; Auclin E; Foulon S; Alves Costa Silva C; Colomba E; Carril L; Derosa L; Flippot R; Mir O; Khoudour N; Blanchet B; Escudier B; Paci A; Albiges L
ESMO Open; 2021 Dec; 6(6):100312. PubMed ID: 34864351
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
[TBL] [Abstract][Full Text] [Related]
17. A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
Shi Y; Ji M; Jiang Y; Yin R; Wang Z; Li H; Wang S; He K; Ma Y; Wang Z; Lu J; Shi M; Shen B; Zhou G; Leong TL; Wang X; Chen C; Feng J
Transl Lung Cancer Res; 2022 Jun; 11(6):1051-1068. PubMed ID: 35832459
[TBL] [Abstract][Full Text] [Related]
18. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. A rapid and sensitive ultra-performance liquid chromatography tandem mass spectrometry method for determination of anlotinib in plasma and dried blood spots: Method development, validation, and clinical application.
Zhang J; Wang W; Du J; Li C; Wang S; Han Y; Wang H; Zong H; Cheng Z; Tian X
Rapid Commun Mass Spectrom; 2022 Nov; 36(21):e9372. PubMed ID: 35918299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
